Rasa Buntinas, MD
Hematology & Oncology · Cedar Rapids, IANPI 1902880966
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $901 of the $1,304 with a category attached, or 69.1%. It is spread thinly across 22 manufacturers, the largest accounting for just 12.4%.
Across 58 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$162
- Pfizer$159
- Johnson & Johnson$141
- AVEO Pharmaceuticals, Inc.$140
- AbbVie$89
- Daiichi Sankyo Inc.$83
- plus $530 from 16 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Food & beverage$90169%
- Education$40331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 4 | $162 |
| Pfizer | 12 | $159 |
| Johnson & Johnson | 3 | $141 |
| AVEO Pharmaceuticals, Inc. | 3 | $140 |
| AbbVie | 4 | $89 |
| Daiichi Sankyo Inc. | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Merck | 2 | $51 |
| AstraZeneca | 3 | $49 |
| Exelixis Inc. | 3 | $46 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| Bristol Myers Squibb | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Gilead | 2 | $27 |
| Sanofi | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| GSK | 1 | $22 |
| Bayer | 1 | $17 |
| Amgen | 1 | $14 |
How this compares
$1,304 in reported general payments places this provider in the 60th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 31 | $501,343 |
| Lenalidomide | 30 | $312,490 |
| KisqaliRibociclib Succinate | 15 | $250,236 |
| JakafiRuxolitinib Phosphate | 11 | $192,741 |
| CalquenceAcalabrutinib Maleate | 12 | $174,832 |
| XareltoRivaroxaban | 38 | $33,780 |
| EliquisApixaban | 38 | $26,015 |
| Anastrozole | 713 | $8,872 |
| Exemestane | 76 | $5,886 |
| Abiraterone Acetate | 24 | $5,073 |
| Letrozole | 220 | $2,617 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $1,090 |
| Raloxifene Hcl | 23 | $995 |
| Gabapentin | 118 | $764 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $501,34331 claims |
| NovartisKisqali | $37 | $250,23615 claims |
| AstraZenecaCalquence | $49 | $174,83212 claims |
| Johnson & JohnsonXarelto | $141 | $33,78038 claims |
| PfizerEliquis | $159 | $26,01538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Cedar Rapids
- William FusselmanCedar Rapids$848
- Samuel WoodCedar Rapids$337
- Chirantan GhoshCedar Rapids$105
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.